Drugs in Development for Herpes Simplex and Varicella Zoster Virus

被引：10

作者：

Birkmann, A. ^{[1
]}

Zimmermann, H. ^{[1
]}

机构：

[1] AiCuris Antiinfect Cures GmbH, Wuppertal, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 01期

关键词：

D O I：

10.1002/cpt.647

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The alpha-herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard-of-care (SoC) is based on nucleoside analogs (NAs), which require specific activation in infected cells. These existing drugs exhibit substantial limitations, warranting the development of new and more effective drugs.

引用

页码：30 / 32

页数：3